Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5399MR)

This product GTTS-WQ5399MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5399MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3559MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ5294MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ2104MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ10269MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ3582MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ2106MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ11471MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ12531MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW